China NMPA Accepts NDA for Sagimet-Partnered Acne Drug Following Positive Phase 3 Results
SGMT has more than doubled off its 52-week low of $1.73 on light trading volume (0.4× avg).
Summary
Sagimet Biosciences announced that its partner Ascletis Bioscience received NMPA acceptance for a New Drug Application for denifanstat for moderate to severe acne in China, following positive topline results from a Phase 3 open-label trial. This is a significant regulatory milestone for a product derived from Sagimet's FASN inhibitor technology, validating its platform and offering potential future revenue streams through its licensing agreement. Additionally, the company completed a Phase 1 pharmacokinetic trial for its denifanstat and resmetirom combination in MASH, with plans to initiate a Phase 2 trial in F4 MASH patients in the second half of 2026, advancing its key pipeline program. Sagimet also secured an exclusive license for resmetirom API from TAPI. While financial results were reported, specific numbers were not provided in the release. Investors will watch for the commercialization of the acne drug in China and the initiation of the MASH Phase 2 trial.
At the time of this announcement, SGMT was trading at $5.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.4M. The 52-week trading range was $1.73 to $11.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.